Basic information Safety Supplier Related

Difluprednate

Basic information Safety Supplier Related

Difluprednate Basic information

Product Name:
Difluprednate
Synonyms:
  • 4-diene-3,20-dione,6-alpha,9-difluoro-11-beta,17,21-trihydroxy-pregna-21-a
  • 6-alpha,9-alpha-difluoroprednisolone17-butyrate21-acetate
  • cetate,17-butyrate
  • myser
  • w6309
  • 6a,9a-difluoroprednisolone 21-acetate 17-butyrate
  • 6ALPHA,9ALPHA-DIFLUOROPREDNISOLONE 21-ACETATE 17-BUTYRATE
  • DIFLUPREDNATE
CAS:
23674-86-4
MF:
C27H34F2O7
MW:
508.55
EINECS:
245-815-4
Product Categories:
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Steroids
  • 23674-86-4
Mol File:
23674-86-4.mol
More
Less

Difluprednate Chemical Properties

Melting point:
191-194°
alpha 
D22 +31.7° (c = 0.5 in dioxane)
Boiling point:
600.3±55.0 °C(Predicted)
Density 
1.1869 (estimate)
storage temp. 
2-8°C
solubility 
Dioxane (Slightly), Methanol (Slightly)
form 
Solid
pka
12.56±0.70(Predicted)
color 
White
More
Less

Safety Information

WGK Germany 
2
RTECS 
TU3831500
HS Code 
2937.29.9095
Toxicity
mouse,LD50,intraperitoneal,146mg/kg (146mg/kg),BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)BEHAVIORAL: FOOD INTAKE (ANIMAL),Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 1066, 1984.

MSDS

More
Less

Difluprednate Usage And Synthesis

Description

Difluprednate is a synthetic glucocorticoid that potently activates the glucocorticoid receptor (Ki = 78 pM). In vivo, ocular administration of difluprednate (0.05% w/v) increases intraocular pressure in sheep. Formulations containing difluprednate have been used to treat diabetic macular edema and inflammation following cataract surgery.

Chemical Properties

White Solid

Originator

Epitopic,Clin Midy,France,1978

Uses

Difluprednate-d3 is the isotope labeled form of Difluprednate (D445925), a corticosteroid (derivative of prednisolone), approved for the treatment of post-operative ocular inflammation.

Definition

ChEBI: Difluprednate is a corticosteroid hormone and a butyrate ester.

Manufacturing Process

Orthoesterification: A mixture of 1 g of 6α,9α-difluoroprednisolone, 10 mg of p-toluenesulfonic acid, 5 cc of dimethylformamide and 3 cc of methyl orthobutyrate is heated for 15 hours on an oil bath at 105°C while a slow stream of nitrogen is passed through the mixture so that the methanol produced as a by-product of the reaction, is distilled off. After addition of several drops of pyridine to neutralize the acid catalyst, the reaction mixture is evaporated under vacuum and there is obtained a solid residue which is taken up with methanol, and filtered. The product is recrystallized from a methylene chloride-methanol mixture to yield 682 mg of 6α,9αdifluoroprednisolone 17α,21-methylorthobutyrate, also identified as 17α,21- (1'-methoxy)-n-butylidenedioxy-6α,9α-difluoro-δ1,4-pregnadiene-11β-ol-3,20- dione, MP 194°C-198°C.
Upon chromatography of the mother liquor on a column of alumina another 338 mg of a crystalline mixture of the epimeric orthobutyrates are isolated.
Hydrolysis: A suspension of 1 g of the 6α,9α-difluoroprednisolone 17α,21- methylorthobutyrate in 10 cc of methanol is treated with 2 cc of a 2 N aqueous solution of oxalic acid and heated on a water bath at 40°-50°C for about 5-10 minutes and, afterwards, the mixture is concentrated under vacuum. The residue is then shaken with water, the insoluble product is filtered off and then dried. The solid material is recrystallized from acetoneether and 6α,9α-difluoroprednisolone 17-butyrate is obtained, MP 193°-196°C
Esterification: A solution of 500 mg of 6α,9α-difluoroprednisolone-17-butyrate in 2.5 cc of pyridine is treated with 1.25 cc of acetic anhydride and the reaction mixture permitted to stand overnight at 0°C. The reaction mixture is then poured into ice water and the crystalline precipitate formed is filtered off and recrystallized from a methylene chloride-ether-petroleum ether mixture to yield 494 mg of 6α,9α-difluoroprednisolone 17-butyrate, 21-acetate; MP 191°- 194°C.

Therapeutic Function

Antiinflammatory

General Description

Difluprednate, 21-(acetyloxy)-6α,9-difluoro-11β-hydroxy-17-(1-oxobutoxy)pregna-1,4-diene-3,20-dione is being developed (phase III) as a topical ophthalmicemulsion to treat inflammatory eye diseases.

DifluprednateSupplier

GUANGZHOU TOPWORK CHEMISTRY CO.,LTD. Gold
Tel
020-87317062 13048089691
Email
852378519@qq.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Chemvon Biotechnology Co., Ltd
Tel
021-50790412
Email
info@chemvon.com
Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Email
zhangsn@titansci.com
LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com